Abstract

Research Article

Prognosis of peripartum cardiomyopathy in sub-Saharan Africa (Burkina Faso South-West PPCM register)

Taryètba André Arthur Seghda*, Théodore Boro, Jean Eudes Bambara, Kadari Cisse, Andrés Miguel Lopez and Patrice Zabsonre

Published: 19 May, 2020 | Volume 5 - Issue 2 | Pages: 109-113

Peripartum cardiomyopathy is one of the curable cardiomyopathy. It’s a severe and frequent disease arising among women of childbearing age. Its evolution in the long-term among some patients leads to chronic heart failure. Our study aims to determine from a prospective cohort, the factors associated with the non-recovery of myocardial function upon 12 months of diagnosis. Sociodemographic, clinical and echocardiographic data were collected at the time of diagnosis and then in months 3, 6 and 12. The outcome was the non-recovery of myocardial function at one year, defined by a left ventricular ejection fraction (LVEF) below 50%. 60 patients were analyzed after 12 months of follow-up. Mortality was about 13.3% and recovery rate of myocardial function reached 42.3%. After logistic regression, delay diagnosis and observance were the factors related to non- recovery of myocardial function.

Read Full Article HTML DOI: 10.29328/journal.jccm.1001096 Cite this Article Read Full Article PDF

Keywords:

Peripartum cardiomyopathy; Prognosis; Delay diagnosis

References

  1. European Society of Gynecology (ESG); Association for European Paediatric Cardiology (AEPC); German Society for Gender Medicine (DGesGM), Regitz-Zagrosek V, Blomstrom Lundqvist C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32: 3147‑ PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21873418
  2. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, et al. ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018; 39: 3165‑ PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30165544
  3. Yaméogo NV, Kagambèga LJ, Seghda TAA, Owona A, et al. Bromocriptine in Management of Peripartum Cardiomyopathy: A Randomized Study on 96 Women in Burkina Faso. J Cardiol Clin Res. 2017; 5: 1098.
  4. Kane Ad, Mbaye M, Ndiaye MB, Diao M, Moreira PM et al.. Évolution et complications thromboemboliques de la myocardiopathie idiopathique du péripartum au CHU de Dakar : étude prospective à propos de 33 cas. J Gynécologie Obstétrique Biol Reprod. 2010; 39: 484‑
  5. Pio M, Afassinou Y, Baragou S, Akue EG, Péssinaba S, et al. Particularités de la cardiomyopathie du péripartum en Afrique: le cas du Togo sur une étude prospective de 41 cas au Centre Hospitalier et Universitaire Sylvanus Olympio de Lomé. PAMJ. 2014; 17: PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189861/
  6. Habedank D, Kühnle Y, Elgeti T, Dudenhausen JW, Haverkamp W, et al. Recovery from peripartum cardiomyopathy after treatment with bromocriptine. Eur Heart J. 2008; 10:1149‑ PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18926768
  7. Meadows WR. Idiopathic Myocardial Failure in the Last Trimester of Pregnancy and the Puerperium. Circulation.1957; 15: 903‑ PubMed: https://www.ncbi.nlm.nih.gov/pubmed/13437416
  8. McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, et al. IPAC Investigators. Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015; 66: 905‑ PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26293760
  9. Evolution et facteurs pronostiques des cardiomyopathies du péripartum à Lomé. Cardiol Trop. 2013; 146.
  10. Vanzetto G. Cardiomyopathie du péripartum. Le Praticien en Anesthésie Réanimation. 2013; 17: 180‑
  11. Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017; 38: 2671‑ PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28934837
  12. Elkayam U, Goland S. Bromocriptine for the treatment of peripartum cardiomyopathy. Circulation. 2010; 121: 1463‑ PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28934837
  13. Witlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy: an ominous diagnosis. Am J Obstet Gynecol. 1997; 176: 182‑ PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9024111
  14. Lindley KJ, Verma AK, Blauwet LA. Peripartum Cardiomyopathy: Progress in Understanding the Etiology, Management, and Prognosis. Heart Fail Clin. 2019; 1529‑ PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30449378
    1. Safirstein JG, Ro AS, Grandhi S, Wang L, Fett JD, et al. Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet. Int J Cardiol. 2012; 154: 27‑ PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20863583

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?